Sequence and Structure Signatures of Cancer Mutation Hotspots in Protein Kinases
暂无分享,去创建一个
[1] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[2] Laxmikant V. Kalé,et al. Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..
[3] Ben J. Powell,et al. Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[4] P. Thomas,et al. Coding single-nucleotide polymorphisms associated with complex vs. Mendelian disease: evolutionary evidence for differences in molecular effects. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[5] J. Skolnick,et al. TM-align: a protein structure alignment algorithm based on the TM-score , 2005, Nucleic acids research.
[6] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[7] T. Hunter,et al. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1 , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[8] Frances M. G. Pearl,et al. MoKCa database—mutations of kinases in cancer , 2008, Nucleic Acids Res..
[9] Gennady M Verkhivker,et al. Cancer driver mutations in protein kinase genes. , 2009, Cancer letters.
[10] L. Schmidt,et al. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants , 2004, Oncogene.
[11] L. Ashman,et al. Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver. , 2003, Leukemia research.
[12] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[13] C. Brooks,et al. Large-scale allosteric conformational transitions of adenylate kinase appear to involve a population-shift mechanism , 2007, Proceedings of the National Academy of Sciences.
[14] Giulio Superti-Furga,et al. Dynamic Coupling between the SH2 and SH3 Domains of c-Src and Hck Underlies Their Inactivation by C-Terminal Tyrosine Phosphorylation , 2001, Cell.
[15] François Stricher,et al. The FoldX web server: an online force field , 2005, Nucleic Acids Res..
[16] R. Dror,et al. A conserved protonation-dependent switch controls drug binding in the Abl kinase , 2009, Proceedings of the National Academy of Sciences.
[17] T. Hunter,et al. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1 , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[18] L. Schmidt,et al. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto‐oncogene: Modeling studies , 2001, Proteins.
[19] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[20] Eric S. Lander,et al. Journey to the Center of Biology , 2000, Science.
[21] G. Parmigiani,et al. Design and analysis issues in genome-wide somatic mutation studies of cancer. , 2009, Genomics.
[22] P. Stenson,et al. Human Gene Mutation Database—A biomedical information and research resource , 2000, Human mutation.
[23] S. Tsai,et al. EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy , 2008, Oncogene.
[24] Michael Gribskov,et al. Protein kinase resource: An integrated environment for phosphorylation research , 2006, Proteins.
[25] Andrew D. Yates,et al. Somatic mutations of the protein kinase gene family in human lung cancer. , 2005, Cancer research.
[26] M. Olivier. A haplotype map of the human genome , 2003, Nature.
[27] Christian Auclair,et al. Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. , 2005, Journal of medicinal chemistry.
[28] Susan S. Taylor,et al. RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. , 2006, Cancer research.
[29] Jun S. Liu,et al. Gibbs motif sampling: Detection of bacterial outer membrane protein repeats , 1995, Protein science : a publication of the Protein Society.
[30] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[31] Yan Zhang,et al. CanPredict: a computational tool for predicting cancer-associated missense mutations , 2007, Nucleic Acids Res..
[32] Ming Tang,et al. PROMALS3D web server for accurate multiple protein sequence and structure alignments , 2008, Nucleic Acids Res..
[33] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[34] Lynn F. Ten Eyck,et al. A helix scaffold for the assembly of active protein kinases , 2008, Proceedings of the National Academy of Sciences.
[35] P. Comoglio,et al. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. , 2002, Cancer research.
[36] J. Reilly,et al. Identification of novel FLT‐3 Asp835 mutations in adult acute myeloid leukaemia , 2001, British journal of haematology.
[37] Elif Ozkirimli,et al. Src kinase activation: A switched electrostatic network , 2006, Protein science : a publication of the Protein Society.
[38] Gennady Verkhivker,et al. Hierarchical Modeling of Activation Mechanisms in the ABL and EGFR Kinase Domains: Thermodynamic and Mechanistic Catalysts of Kinase Activation by Cancer Mutations , 2009, PLoS Comput. Biol..
[39] A. Cavalli,et al. Protein conformational transitions: the closure mechanism of a kinase explored by atomistic simulations. , 2009, Journal of the American Chemical Society.
[40] Alfonso Valencia,et al. Extraction of human kinase mutations from literature, databases and genotyping studies , 2009, BMC Bioinformatics.
[41] Stefan Fröhling,et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. , 2007, Cancer cell.
[42] Matthew Meyerson,et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.
[43] Svend Kjær,et al. Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain* , 2006, Journal of Biological Chemistry.
[44] T. Naoe,et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.
[45] A. Sparks,et al. The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.
[46] Renate Griffith,et al. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. , 2004, Journal of molecular graphics & modelling.
[47] M. Olivier. A haplotype map of the human genome. , 2003, Nature.
[48] M. Vihinen,et al. BTKbase: the mutation database for X‐linked agammaglobulinemia , 2006, Human mutation.
[49] Michel Schneider,et al. UniProtKB/Swiss-Prot. , 2007, Methods in molecular biology.
[50] K. Wilson,et al. Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* , 2004, Journal of Biological Chemistry.
[51] M. Michael Gromiha,et al. CUPSAT: prediction of protein stability upon point mutations , 2006, Nucleic Acids Res..
[52] T. Sawyer. Novel oncogenic protein kinase inhibitors for cancer therapy. , 2004, Current medicinal chemistry. Anti-cancer agents.
[53] Benoît Roux,et al. Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories , 2009, Proceedings of the National Academy of Sciences.
[54] L. Mulligan,et al. Molecular Implications of RET Mutations for Pheochromocytoma Risk in Multiple Endocrine Neoplasia 2 , 2006, Annals of the New York Academy of Sciences.
[55] Laura Sepp-Lorenzino,et al. Analysis of the activating mutations within the activation loop of leukemia targets Flt-3 and c-Kit based on protein homology modeling. , 2004, Journal of molecular graphics & modelling.
[56] Susan S. Taylor,et al. Congenital disease SNPs target lineage specific structural elements in protein kinases , 2008, Proceedings of the National Academy of Sciences.
[57] A. Dobrovic,et al. Sensitive detection of KIT D816V in patients with mastocytosis. , 2006, Clinical chemistry.
[58] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[59] Jun S. Liu,et al. Detecting subtle sequence signals: a Gibbs sampling strategy for multiple alignment. , 1993, Science.
[60] H. Erickson,et al. High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia , 2009, Leukemia.
[61] Tony Fletcher,et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer , 2008, Nature Genetics.
[62] Susan S. Taylor,et al. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism , 2006, Proceedings of the National Academy of Sciences.
[63] G. Casari,et al. Automatic extraction of mutations from Medline and cross-validation with OMIM. , 2004, Nucleic acids research.
[64] S. Eckhardt,et al. Tyrosine kinase inhibitors in cancer therapy. , 2008, Anti-cancer agents in medicinal chemistry.
[65] P. Stenson,et al. Human Gene Mutation Database (HGMD®): 2003 update , 2003, Human mutation.
[66] T. Zhou,et al. Crystal Structure of the T315I Mutant of Abl Kinase , 2007, Chemical biology & drug design.
[67] L. Ashman,et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.
[68] P. Accornero,et al. K252a inhibits the oncogenic properties of Met, the HGF receptor , 2002, Oncogene.
[69] T. Hunter,et al. The protein kinases of budding yeast: six score and more. , 1997, Trends in biochemical sciences.
[70] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[71] Benoît Roux,et al. Src Kinase Conformational Activation: Thermodynamics, Pathways, and Mechanisms , 2008, PLoS Comput. Biol..
[72] Philip E. Bourne,et al. The RCSB PDB information portal for structural genomics , 2005, Nucleic Acids Res..
[73] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[74] F. Lozupone,et al. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma , 2006, Oncogene.
[75] S. Gabriel,et al. High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.
[76] L. Johnson,et al. Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.
[77] Fotini Tzortzatou-Stathopoulou,et al. Conformational dynamics of the EGFR kinase domain reveals structural features involved in activation , 2009, Proteins.
[78] I. Weinstein. Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.
[79] Ming-Li Xiang,et al. Detailed conformational dynamics of juxtamembrane region and activation loop in c‐Kit kinase activation process , 2008, Proteins.
[80] G. Cheetham. Novel protein kinases and molecular mechanisms of autoinhibition. , 2004, Current opinion in structural biology.
[81] B. Roux,et al. Anatomy of a structural pathway for activation of the catalytic domain of Src kinase Hck , 2007, Proteins.
[82] T. Hunter,et al. Evolution of protein kinase signaling from yeast to man. , 2002, Trends in biochemical sciences.
[83] Francis S Collins,et al. Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. , 2007, Scientific American.
[84] C. Orengo,et al. Cancer‐associated mutations are preferentially distributed in protein kinase functional sites , 2009, Proteins.
[85] T. Hunter,et al. Signaling—2000 and Beyond , 2000, Cell.
[86] Adrian A Canutescu,et al. Access the most recent version at doi: 10.1110/ps.03154503 References , 2003 .
[87] Dietmar Schomburg,et al. Computational modeling of protein mutant stability: analysis and optimization of statistical potentials and structural features reveal insights into prediction model development , 2007, BMC Structural Biology.
[88] Francis S. Collins,et al. Mapping the cancer genome , 2007 .
[89] Gennady Verkhivker,et al. Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. , 2009, Biophysical journal.
[90] Alexander D. MacKerell,et al. Development and current status of the CHARMM force field for nucleic acids , 2000, Biopolymers.
[91] D. Williams,et al. Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights. , 2004, Current medicinal chemistry.
[92] Maria Jesus Martin,et al. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003 , 2003, Nucleic Acids Res..
[93] A. Sali,et al. Modeling of loops in protein structures , 2000, Protein science : a publication of the Protein Society.
[94] Andrew D. Yates,et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer , 2005, Nature Genetics.
[95] M. Stratton,et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.
[96] Balazs Halmos,et al. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] Benoît Roux,et al. Flexibility and charge asymmetry in the activation loop of Src tyrosine kinases , 2009, Proteins.
[98] Joaquín Dopazo,et al. PupaSNP Finder: a web tool for finding SNPs with putative effect at transcriptional level , 2004, Nucleic Acids Res..
[99] E S Lander,et al. Genomics: journey to the center of biology. , 2000, Science.
[100] A. Bardelli,et al. Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[101] Gerard Manning,et al. Structural and Functional Diversity of the Microbial Kinome , 2007, PLoS biology.
[102] M. Vihinen,et al. KinMutBase: A registry of disease‐causing mutations in protein kinase domains , 2005, Human mutation.
[103] Rakesh Nagarajan,et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. , 2008, Blood.
[104] B. Peters,et al. Distinguishing cancer-associated missense mutations from common polymorphisms. , 2007, Cancer research.
[105] A. Sali,et al. Comparative protein structure modeling of genes and genomes. , 2000, Annual review of biophysics and biomolecular structure.
[106] Philip E. Bourne,et al. Structural Evolution of the Protein Kinase–Like Superfamily , 2005, PLoS Comput. Biol..
[107] Kevan M Shokat,et al. Features of selective kinase inhibitors. , 2005, Chemistry & biology.
[108] Alexander D. MacKerell,et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.
[109] Sreenath V. Sharma,et al. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. , 2007, Genes & development.
[110] D. Maritano,et al. Two mutations affecting conserved residues in the Met receptor operate via different mechanisms , 2000, Oncogene.
[111] Carol Beth Post,et al. An electrostatic network and long‐range regulation of Src kinases , 2008, Protein science : a publication of the Protein Society.
[112] J. Kuriyan,et al. The Conformational Plasticity of Protein Kinases , 2002, Cell.
[113] Zhaohui S. Qin,et al. A second generation human haplotype map of over 3.1 million SNPs , 2007, Nature.
[114] L. Serrano,et al. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. , 2002, Journal of molecular biology.
[115] S. Fröhling,et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. , 2007, Blood.
[116] P. Stenson,et al. Human Gene Mutation Database (HGMD , 2003 .
[117] John Kuriyan,et al. Protein-protein interactions in the allosteric regulation of protein kinases. , 2006, Current opinion in structural biology.
[118] C. Sawyers. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. , 2003, Genes & development.
[119] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[120] G. Parmigiani,et al. The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.
[121] Susan S. Taylor,et al. Regulation of protein kinases; controlling activity through activation segment conformation. , 2004, Molecular cell.
[122] M. Meyerson,et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.
[123] L. Mulligan,et al. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. , 2006, Cancer research.
[124] Jun S. Liu,et al. Gapped alignment of protein sequence motifs through Monte Carlo optimization of a hidden Markov model , 2004, BMC Bioinformatics.
[125] Nathaniel J. Traaseth,et al. Allosteric cooperativity in protein kinase A , 2008, Proceedings of the National Academy of Sciences.
[126] J. Haines,et al. Genome-wide association study identifies a novel breast cancer susceptibility locus at 6q25.1 , 2009, Nature Genetics.
[127] D. Altshuler,et al. Completing the map of human genetic variation , 2007, Nature.
[128] L. Schmidt,et al. Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src , 2000, Oncogene.
[129] P. Comoglio,et al. Mutations in the met Oncogene Unveil a “Dual Switch” Mechanism Controlling Tyrosine Kinase Activity* , 2003, Journal of Biological Chemistry.
[130] L. Schmidt,et al. Activating mutations for the met tyrosine kinase receptor in human cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[131] S. Knapp,et al. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[132] L. Mulligan,et al. RET Signaling in Endocrine Tumors: Delving Deeper into Molecular Mechanisms , 2007, Endocrine pathology.
[133] John Kuriyan,et al. An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.
[134] M. Campbell,et al. PANTHER: a library of protein families and subfamilies indexed by function. , 2003, Genome research.
[135] F. Lu,et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. , 2004, Molecular cell.
[136] K. Sirotkin,et al. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. , 1999, Genome research.
[137] N. Schork,et al. Prediction of cancer driver mutations in protein kinases. , 2008, Cancer research.
[138] Nicholas J. Schork,et al. Accurate prediction of deleterious protein kinase polymorphisms , 2007, Bioinform..
[139] B. Druker,et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. , 2003, Blood.
[140] A. F. Neuwald,et al. Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component? , 2005, Journal of molecular biology.
[141] Antonella Isacchi,et al. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. , 2007, Cancer research.
[142] Mauno Vihinen,et al. KinMutBase, a database of human disease-causing protein kinase mutations , 1999, Nucleic Acids Res..
[143] D. Cooper,et al. Protein Kinases as Therapeutic Targets , 2000, Pharmaceutical Research.